Register for our free email digests:
Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.
Support is strong for continuing EU co-ordination on health technology assessment, according to a report on the responses to a consultation on the topic. An impact assessment on what will follow the EUnetHTA Joint Action 3 will come in late 2017.
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
The first pilot for the Benelux joint pricing and reimbursement process has failed. Negotiations between Vertex and the ministries of health in Belgium and the Netherlands have ended with no agreement on price for cystic fibrosis drug Orkambi.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.